Paolo Tarantino· @PTarantinoMD · X·· 2 天前评分70
正文 · 原文
🇨🇳 PANKU-Breast01: the HER3-EGFR bispecific TOPO1 ADC Iza-Bren improved PFS vs chemo in HR+/HER2- MBC (OS immature). High rate of hematologic toxicity, with ~50% G3+ anemia, neutropenia and thrombocytopenia, and most patients requiring dose reductions⚠️. #ESMO26 #ESMOAmbassadors
807 浏览 · 9 赞 · 3 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Paolo Tarantino · x.com